Background: Bevacizumab plus interferon-α2a (IFN) prolongs progression-free survival to>
10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell …

En Abstract Background: Renal cell carcinoma (RCC) is the most common form of kidney
cancer. Immunotherapy with interferon-α (IFNα) and interleukin-2 (IL-2) has been the …

Background Although targeted therapies (ie, tyrosine kinase inhibitors and antiangiogenesis
agents) are effective as first-line treatment of metastatic renal cell carcinoma (mRCC) …

Background: Two new agents have recently been licensed for use in the treatment of
metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review …

Background: The vascular endothelial growth factor inhibitor bevacizumab (BEV) given in
combination with interferon-α-2a (IFN), and the tyrosine kinase inhibitors (TKIs) sunitinib …

Study Type–Therapy (economic) Level of Evidence 2b What's known on the subject? and
What does the study add? Cost‐effectiveness of new targeted molecular therapies in …

Targeted therapy for advanced renal cell carcinoma (RCC) has recently expanded the
available treatment options for patients with these malignancies. The rapid introduction of …

Angiogenesis inhibitors have become standard of care for advanced and/or metastatic renal
cell carcinoma (RCC), but data on the impact of adverse events (AE s) and treatment …

Objectives: The objective of this study was to describe treatment patterns, survival,
healthcare use and costs in patients with metastatic renal cell carcinoma (mRCC) in a real …

Purpose The aim of this study was to compare the cost-effectiveness of cabozantinib with the
standard of care in England in adult patients with advanced renal cell carcinoma (aRCC) …